The benefits of vaccination with recombinant zoster vaccine outweigh safety concerns in immunocompromised populations, according to a systematic review of studies involving multiple patient groups.
Francis A. Farraye, MD, MSc, a gastroenterologist and professor of medicine at Mayo Clinic in Florida, in Jacksonville, who was a co-author of the review, stressed the importance of herpes zoster prophylaxis in patients who are immunocompromised, due to either their medical condition or